Total Knee Arthroplasty Is Safe in Jehovah's Witness Patients-A 12-Year Perspective.
Aged
Aged, 80 and over
Anemia
/ therapy
Antifibrinolytic Agents
/ therapeutic use
Arthroplasty, Replacement, Knee
/ adverse effects
Blood Loss, Surgical
/ prevention & control
Blood Transfusion
Epoetin Alfa
/ therapeutic use
Female
Folic Acid
/ therapeutic use
Hematinics
/ therapeutic use
Hemoglobins
/ analysis
Hemostasis, Surgical
Humans
Iron Compounds
/ therapeutic use
Jehovah's Witnesses
Male
Middle Aged
Postoperative Hemorrhage
/ etiology
Preoperative Care
Retrospective Studies
Tranexamic Acid
/ therapeutic use
Treatment Outcome
Journal
The journal of knee surgery
ISSN: 1938-2480
Titre abrégé: J Knee Surg
Pays: Germany
ID NLM: 101137599
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
pubmed:
9
1
2019
medline:
19
5
2020
entrez:
9
1
2019
Statut:
ppublish
Résumé
Despite the evolution of blood management protocols, total knee arthroplasty (TKA) occasionally requires allogeneic blood transfusion. This poses a particular challenge for Jehovah's Witnesses (JW) who believe that the Bible strictly prohibits the use of blood products. The aim of this study was to compare JW and a matched-control cohort of non-JW candidates undergoing TKA to assess the safety using modern blood management protocols. Fifty-five JW patients (63 knees) who underwent TKA at our institution between 2005 and 2017 were matched to 63 non-JW patients (63 knees). Patient demographics, intraoperative details, and postoperative complications including in-hospital complications, revisions, and 90-day readmissions were collected and compared between the groups. Additionally, subgroup analysis was performed comparing JW patients who were administered tranexamic acid (TXA) between the two groups. Baseline demographics did not vary significantly between the study cohorts. The mean follow-up was 3.1 years in both the JW and non-JW cohorts. Postoperative complications, including in-hospital complications (7.9 vs. 4.8%;
Identifiants
pubmed: 30620987
doi: 10.1055/s-0038-1676372
doi:
Substances chimiques
Antifibrinolytic Agents
0
Hematinics
0
Hemoglobins
0
Iron Compounds
0
Epoetin Alfa
64FS3BFH5W
Tranexamic Acid
6T84R30KC1
Folic Acid
935E97BOY8
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-41Informations de copyright
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Déclaration de conflit d'intérêts
None declared.